Zoetis Inc. $ZTS Shares Bought by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 11.3% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,483 shares of the company’s stock after purchasing an additional 150 shares during the period. Ashton Thomas Securities LLC’s holdings in Zoetis were worth $231,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ZTS. Brighton Jones LLC grew its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the period. Merit Financial Group LLC lifted its stake in shares of Zoetis by 62.3% in the 1st quarter. Merit Financial Group LLC now owns 12,178 shares of the company’s stock valued at $2,005,000 after purchasing an additional 4,676 shares in the last quarter. Vest Financial LLC purchased a new stake in shares of Zoetis during the 1st quarter worth about $207,000. Intellectus Partners LLC increased its position in Zoetis by 19.6% during the 1st quarter. Intellectus Partners LLC now owns 6,849 shares of the company’s stock worth $1,128,000 after purchasing an additional 1,121 shares in the last quarter. Finally, IAM Advisory LLC raised its holdings in Zoetis by 0.8% in the first quarter. IAM Advisory LLC now owns 10,102 shares of the company’s stock valued at $1,663,000 after buying an additional 80 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $146.45 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a 50-day moving average of $149.79 and a two-hundred day moving average of $155.14. The stock has a market cap of $64.91 billion, a P/E ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ZTS shares. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and lowered their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.